Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$1.4 - $2.77 $102,419 - $202,644
-73,157 Reduced 78.06%
20,562 $41,000
Q1 2024

May 15, 2024

BUY
$1.39 - $2.21 $130,269 - $207,118
93,719 New
93,719 $137,000
Q2 2023

Aug 14, 2023

SELL
$2.38 - $3.67 $5,366 - $8,275
-2,255 Reduced 16.85%
11,131 $32,000
Q1 2023

May 15, 2023

BUY
$1.15 - $3.0 $15,393 - $40,158
13,386 New
13,386 $40,000
Q3 2022

Nov 14, 2022

SELL
$1.83 - $2.93 $1,601 - $2,563
-875 Reduced 3.4%
24,870 $60,000
Q2 2022

Aug 16, 2022

BUY
$1.77 - $3.87 $45,568 - $99,633
25,745 New
25,745 $48,000
Q1 2021

May 18, 2021

SELL
$6.93 - $9.63 $69,868 - $97,089
-10,082 Closed
0 $0
Q4 2020

Feb 17, 2021

BUY
$4.28 - $7.87 $43,150 - $79,345
10,082 New
10,082 $77,000

Others Institutions Holding SCYX

About SCYNEXIS INC


  • Ticker SCYX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 32,651,800
  • Market Cap $33M
  • Description
  • SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of vario...
More about SCYX
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.